[go: up one dir, main page]

PH12013500980A1 - Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof - Google Patents

Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Info

Publication number
PH12013500980A1
PH12013500980A1 PH1/2013/500980A PH12013500980A PH12013500980A1 PH 12013500980 A1 PH12013500980 A1 PH 12013500980A1 PH 12013500980 A PH12013500980 A PH 12013500980A PH 12013500980 A1 PH12013500980 A1 PH 12013500980A1
Authority
PH
Philippines
Prior art keywords
valsartan
lercanidipine hydrochloride
preparation
present
complex formulation
Prior art date
Application number
PH1/2013/500980A
Inventor
Young Sik Chung
Jae Hyeon Juhn
Min Young Jung
Dong Kyu Kim
Ju Hyun Kim
Ree Sun Kim
Sung Il Kim
Yoo Rin Kim
Sung Hack Lee
Hee Dong Park
Seong Jae Park
Soo Ah Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500980(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PH12013500980A1 publication Critical patent/PH12013500980A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydrochloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.
PH1/2013/500980A 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof PH12013500980A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
PH12013500980A1 true PH12013500980A1 (en) 2013-07-08

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500980A PH12013500980A1 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Country Status (18)

Country Link
EP (1) EP2648730A4 (en)
KR (1) KR101414814B1 (en)
CN (1) CN103249415B (en)
AR (1) AR084195A1 (en)
AU (1) AU2011339150B2 (en)
BR (1) BR112013013415A2 (en)
CL (1) CL2013001626A1 (en)
CO (1) CO6721030A2 (en)
DO (1) DOP2013000115A (en)
EA (1) EA201390844A1 (en)
IL (1) IL226449A0 (en)
MX (1) MX2013005716A (en)
PE (1) PE20140699A1 (en)
PH (1) PH12013500980A1 (en)
SG (1) SG190326A1 (en)
UA (1) UA108277C2 (en)
UY (1) UY33772A (en)
WO (1) WO2012077968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 Compound preparation of lercanidipine and atorvastatin
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (en) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
CA2547657A1 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.

Also Published As

Publication number Publication date
EP2648730A2 (en) 2013-10-16
DOP2013000115A (en) 2014-07-31
AU2011339150B2 (en) 2015-09-10
UA108277C2 (en) 2015-04-10
WO2012077968A3 (en) 2012-07-26
IL226449A0 (en) 2013-07-31
AU2011339150A1 (en) 2013-06-06
BR112013013415A2 (en) 2019-09-24
WO2012077968A2 (en) 2012-06-14
EP2648730A4 (en) 2014-08-06
EA201390844A1 (en) 2013-11-29
CN103249415B (en) 2017-12-12
KR20120089787A (en) 2012-08-13
CL2013001626A1 (en) 2013-10-04
AR084195A1 (en) 2013-04-24
KR101414814B1 (en) 2014-07-21
UY33772A (en) 2012-07-31
MX2013005716A (en) 2013-06-12
SG190326A1 (en) 2013-06-28
CN103249415A (en) 2013-08-14
CO6721030A2 (en) 2013-07-31
PE20140699A1 (en) 2014-06-13

Similar Documents

Publication Publication Date Title
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MD4563B1 (en) Co-micronisation product comprising ulipristal acetate
IN2014DN01619A (en)
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
PH12014502836B1 (en) Medicament form for release of active ingredients
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
MX357704B (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
BR112014004737A2 (en) Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
WO2012007758A3 (en) Pharmaceutical formulations
TN2013000212A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
PH12013502080A1 (en) Modified release pharmaceutical compositions of desvenlafaxine
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet